Role of autologus platelet rich plasma in early stages of osteoarthritis of knee

Abstract

Background: In the treatment of early stage osteoarthritis with intraarticular injection there are many available options as steroid, hyaluronic acid and platelet rich plasma. Platelet-rich plasma (PRP) is a concentrate of autologous blood growth factors which has been shown to provide some symptomatic relief in early osteoarthritis (OA) of the knee. The Aim of this study is to evaluate the effectiveness of Platelet Rich Plasma in reducing pain and improving physical function. Materials and Method: A Prospective study of 30 Patient with Early stage ( Stage 1 and 2 ) of Osteoarthritis who satisfies the inclusion criteria from August 2019 to June 2020 in Bapuji Hospital and Chigateri Government Hospital attached to JJM Medical College, Davangere. All patients were injected with autologous platelet rich plasma and evaluated for VAS (Visual analog scale) and WOMAC (Western Ontario and McMaster Universities) scoring system on (pre-procedure) day 0 and (post-procedure) at the end of 4 weeks, 12 weeks,24weeks. Result: In our study age distribution revealed mean age in is to be 46.6 years. The gender distribution of 66.66% of male and 33.33% of female. The mean BMI of the patient is 25.65. In this study 43.33% belong to Grade 1 and 56.66% patient belong to Grade 2 classification according to Kellgren Lawrence classification of OA knee. The Global WOMAC showed a mean of 61.3 at pre injection period which decreased to 48.46 at 4 weeks follow up and 37.90 at 12 weeks and declining to 27.33 at 24week.The mean VAS score showed 6.33 at pre injection period which decreased to 4.4 at 4 weeks follow up and 2.5 at 12 weeks and declining to 1.76 at 24week. Conclusion: Platelet-rich plasma therapy is a simple, low-cost and minimally invasive intervention which is feasible to deliver to treat degenerative lesions of articular cartilage of the knee.